Royal Bank of Canada
PROF

Royal Bank of Canada’s Profound Medical PROF Stock Holding History

Royal Bank of Canada’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27M Sell
491,495
-1,565
-0.3% -$10.5K ﹤0.01% 2923
2026
Q1 		$3.19M Buy
493,060
+19,842
+4% +$137K ﹤0.01% 2745
2025
Q4 		$3.73M Sell
473,218
-12,702
-3% -$81.6K ﹤0.01% 2661
2025
Q3 		$2.38M Buy
485,920
+26,001
+6% +$133K ﹤0.01% 3257
2025
Q2 		$2.71M Buy
459,919
+23,922
+5% +$126K ﹤0.01% 3050
2025
Q1 		$2.54M Buy
435,997
+14,795
+4% +$102K ﹤0.01% 2773
2024
Q4 		$3.16M Buy
421,202
+19,877
+5% +$153K ﹤0.01% 2678
2024
Q3 		$3.19M Buy
401,325
+96
+0% +$867 ﹤0.01% 2637
2024
Q2 		$3.37M Buy
401,229
+1,103
+0.3% +$8.89K ﹤0.01% 2503
2024
Q1 		$3.41M Sell
400,126
-33
-0% -$275 ﹤0.01% 2490
2023
Q4 		$3.4M Sell
400,159
-1,674
-0.4% -$15.9K ﹤0.01% 2585
2023
Q3 		$4.1M Buy
401,833
+1,153
+0.3% +$12K ﹤0.01% 2248
2023
Q2 		$5.21M Sell
400,680
-314
-0.1% -$3.9K ﹤0.01% 2069
2023
Q1 		$3.73M Buy
400,994
+1,374
+0.3% +$15.9K ﹤0.01% 2313
2022
Q4 		$4.35M Buy
399,620
+13,000
+3% +$70.9K ﹤0.01% 2251
2022
Q3 		$1.56M Sell
386,620
-386
-0.1% -$2.6K ﹤0.01% 3053
2022
Q2 		$2.82M Buy
387,006
+65,305
+20% +$516K ﹤0.01% 2574
2022
Q1 		$2.9M Buy
321,701
+59,998
+23% +$578K ﹤0.01% 2718
2021
Q4 		$2.94M Buy
261,703
+8,927
+4% +$111K ﹤0.01% 2824
2021
Q3 		$3.7M Buy
252,776
+846
+0.3% +$12.9K ﹤0.01% 2555
2021
Q2 		$4.12M Buy
251,930
+245,850
+4,044% +$4.57M ﹤0.01% 2452
2021
Q1 		$122K Sell
6,080
-2,234
-27% -$53.6K ﹤0.01% 5324
2020
Q4 		$171K Buy
8,314
+2,453
+42% +$45.1K ﹤0.01% 4965
2020
Q3 		$103K Buy
5,861
+366
+7% +$5.82K ﹤0.01% 4960
2020
Q2 		$93K Buy
5,495
+1,141
+26% +$14.4K ﹤0.01% 4894
2020
Q1 		$43K Buy
4,354
+654
+18% +$8.48K ﹤0.01% 5232
2019
Q4 		$40K Buy
+3,700
New +$34.1K ﹤0.01% 5544

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.77B AUM 38.11% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Royal Bank of Canada's PROF Position: Q2 2026 in Review

Royal Bank of Canada reduced its Profound Medical (PROF) stake by 0.32% in Q2 2026, selling an estimated $10.5K and leaving 491,495 shares worth $3.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

Royal Bank of Canada first reported a position in PROF in Q4 2019 and has held it in 27 quarters since. The position peaked at $5.21M in Q2 2023. 55 funds tracked by Wall St. Rank hold PROF as of Q2 2026.

  • Royal Bank of Canada held 491,495 shares of Profound Medical worth $3.27M as of Q2 2026.
  • Royal Bank of Canada sold 1,565 Profound Medical shares in Q2 2026, an estimated $10.5K.
  • Profound Medical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2923 holding.
  • Royal Bank of Canada first reported a position in Profound Medical in Q4 2019 and has held it in 27 quarters since.
  • Royal Bank of Canada's Profound Medical position peaked at $5.21M in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.